Showing 1-8 of 8 "Lymphoma"

Status: Open Not Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Erick Villarreal-Williams

Phone: 713.441.9775

This is an open-label, multicenter, phase 2 study to evaluate the efficacy and safety of oral MLN9708 in adult patients with follicular lymphoma (FL) that is relapsed and/or refractory to prior treatment. ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Ramon Guardiola

Phone: 713.441.3958

This is an open-label, dose-escalation/dose-expansion study of INCB057643 in subjects with advanced malignancies. Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic a ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Karen Woodard

Phone: 713.441.4332

Open-label, dose-escalation study in subjects with previously treated B-cell malignancies to find maximum tolerated dose (MTD) or pharmacologic active dose of a PI3Kδ inhibitor, INCB050465, as monotherapy and in combination with: itacitinib (INC ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Karen Woodard

Phone: 713.441.4332

The purpose of this study is to evaluate the safety/tolerability and efficacy of itacitinib in combination with ibrutinib in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Karen Woodard

Phone: 713.441.4332

This study is an open-label, multicenter, phase 1, dose escalation study of TAK-659 in adult patients with advanced solid tumor and lymphoma malignancies. This study will be the first to administer TAK-659 to humans. The patient population durin ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Alice Pavlak

Phone: 713..44.1.3246

This open-label, multicenter, global study is designed to determine the recommended phase 2 dose, safety, efficacy, and pharmacokinetics/pharmacodynamics of durvalumab in subjects with certain lymphoma subtypes or CLL. Globally, 253 subjects may ... Read more >

Status: Open Not Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Karen Woodard

Phone: 713.441.4332

This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics of GDC-0199 (ABT-199) administered in combination with obinutuzumab to patients with relapsed/refractory or previously untreated chronic lymphocytic ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Alice Pavlak

Phone: 713..44.1.3246

This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety of CUDC-907 monotherapy and R-907 (rituximab in combination with CUDC-907) in subjects 18 years and older with Relapsed/Refractory (RR) MYC-altered Dif ... Read more >